164 related articles for article (PubMed ID: 14556779)
21. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
22. Novel FLT3 tyrosine kinase inhibitors.
Levis M; Small D
Expert Opin Investig Drugs; 2003 Dec; 12(12):1951-62. PubMed ID: 14640939
[TBL] [Abstract][Full Text] [Related]
23. The flt3 ligand: a hematopoietic stem cell factor whose activities are distinct from steel factor.
Lyman SD; Brasel K; Rousseau AM; Williams DE
Stem Cells; 1994; 12 Suppl 1():99-107; discussion 108-10. PubMed ID: 7535149
[TBL] [Abstract][Full Text] [Related]
24. Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner.
Mitina O; Warmuth M; Krause G; Hallek M; Obermeier A
Ann Hematol; 2007 Nov; 86(11):777-85. PubMed ID: 17668209
[TBL] [Abstract][Full Text] [Related]
25. Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects.
Heinrich MC
Mini Rev Med Chem; 2004 Mar; 4(3):255-71. PubMed ID: 15032673
[TBL] [Abstract][Full Text] [Related]
26. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Naoe T; Kiyoe H; Yamamoto Y; Minami Y; Yamamoto K; Ueda R; Saito H
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S27-30. PubMed ID: 11587362
[TBL] [Abstract][Full Text] [Related]
27. Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.
Longati P; Comoglio PM; Bardelli A
Curr Drug Targets; 2001 Mar; 2(1):41-55. PubMed ID: 11465538
[TBL] [Abstract][Full Text] [Related]
28. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
Doepfner KT; Boller D; Arcaro A
Crit Rev Oncol Hematol; 2007 Sep; 63(3):215-30. PubMed ID: 17658267
[TBL] [Abstract][Full Text] [Related]
29. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
Yao Q; Nishiuchi R; Kitamura T; Kersey JH
Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
[TBL] [Abstract][Full Text] [Related]
30. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
31. [Molecular mechanisms in leukemogenesis].
Mitani K
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1107-12. PubMed ID: 12145988
[TBL] [Abstract][Full Text] [Related]
32. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
[TBL] [Abstract][Full Text] [Related]
33. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
[TBL] [Abstract][Full Text] [Related]
34. Molecular genetics of human leukemias: new insights into therapy.
Gilliland DG
Semin Hematol; 2002 Oct; 39(4 Suppl 3):6-11. PubMed ID: 12447846
[TBL] [Abstract][Full Text] [Related]
35. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
36. FLT3: receptor and ligand.
Drexler HG; Quentmeier H
Growth Factors; 2004 Jun; 22(2):71-3. PubMed ID: 15253381
[TBL] [Abstract][Full Text] [Related]
37. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
Robinson LJ; Xue J; Corey SJ
Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C
J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163
[TBL] [Abstract][Full Text] [Related]
39. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.
Griffith J; Black J; Faerman C; Swenson L; Wynn M; Lu F; Lippke J; Saxena K
Mol Cell; 2004 Jan; 13(2):169-78. PubMed ID: 14759363
[TBL] [Abstract][Full Text] [Related]
40. FLT3: ITDoes matter in leukemia.
Levis M; Small D
Leukemia; 2003 Sep; 17(9):1738-52. PubMed ID: 12970773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]